Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial.

Publication Year: 2022

DOI:
10.1183/13993003.00483-2022

PMCID:
PMC9684623

PMID:
35777775

Journal Information

Full Title: Eur Respir J

Abbreviation: Eur Respir J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: P.A.J. Crosbie reports consulting fees and stock options from Everest Detection; lecture honoraria from AstraZeneca; designing a questionnaire for Novartis; and designing a study for North West eHealth; outside the submitted work. D. Baldwin reports lecture honoraria from MSD, AstraZeneca, Roche and BMS; outside the submitted work. K.N. Franks reports grants from Yorkshire Cancer Research, AstraZeneca and CRUK/AstraZeneca; consulting fees from AstraZeneca; lecture honoraria and payment for expert testimony from AstraZeneca, Roche and Takeda; advisory board membership with Amgen, AstraZeneca, BMS, Lilley and Takeda; outside the submitted work. The remaining authors have no conflicts of interest relevant to this article to disclose."

Evidence found in paper:

"Support statement: This work was funded by Yorkshire Cancer Research (award reference L403). From September 2021, P. Alexandris was supported by the Barts Hospital Charity (MRC&U0036). From January 2021, S.L. Quaife was supported by the Barts Hospital Charity (MRC&U0036). P.A.J. Crosbie is supported by the Manchester National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007). Funding information for this article has been deposited with the Crossref Funder Registry."

Evidence found in paper:

"The YLST study is registered at the ISRCTN registry with identifier ISRCTN42704678. In order to meet our ethical obligation to responsibly share data generated by clinical trials, YLST operates a transparent data-sharing request process. Anonymous data will be available for request once the study has published the final proposed analyses. Researchers wishing to use the data will need to complete a request for data-sharing form describing a methodologically sound proposal. The form will need to include the objectives, what data are requested, timelines for use, intellectual property and publication rights, data release definition in the contract and participant informed consent, etc. A data-sharing agreement from the sponsor may be required."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025